2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
Species | Mouse |
Synonyms | Interferon lambda-2; IFN-lambda-2; Interleukin-28A (IL-28A) |
Accession | Q4VK74 |
Amino Acid Sequence | Asp20-Val193, with C-terminal 8*His |
Expression System | HEK293 |
Molecular Weight | 25-30 kDa (Reducing) |
Purity | >95% by SDS-PAGE and HPLC. |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | His Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference | Nat Immunol. 2003 Jan;4(1):63-8. Epub 2002 Dec 2. |
Background
Interferon lambda 2 (IFN-λ2), also known as interleukin-28A (IL-28A), is a type III interferon that belongs to the interferon lambda family. IFN-λ2 is produced in response to viral infections and plays a crucial role in the innate immune response against viruses. It exerts antiviral effects by inducing the expression of interferon-stimulated genes (ISGs) that inhibit viral replication and spread. IFN-λ2 signals through the IFN-λ receptor complex, which consists of IL-10R2 and IL-28Rα subunits, leading to the activation of downstream signaling pathways involved in antiviral defense. IFN-λ2 is considered a promising therapeutic agent for the treatment of viral infections due to its potent antiviral properties and reduced potential for side effects compared to type I interferons.
Picture
Picture
SDS-PAGE
SEC-HPLC
>95% as determined by SEC-HPLC.
